~~<i id='3D340D810F'><strike id='3D340D810F'><tt id='3D340D810F'><pre id='3D340D810F'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：comprehensive 2025-10-06 11:47:31 Page View：8884

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves
Next article： New air purifier tech could be key to improving indoor air quality

explore

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

After sickle

MollyFerguson/STATTheapprovalFridayofBluebirdBio’sgenetherapyforsicklecelldiseaseshouldhavebeenamome

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Community Health Systems hospitals under DOJ investigation

BRENDANSMIALOWSKI/AFPviaGettyImagesCommunityHealthSystemsisfacinganewfederalprobeintoitshospitalbill